Conference Correspondent

Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

Conference Correspondent - ASCO 2019 - Chronic Lymphocytic Leukemia

This phase 1b/2 trial evaluated acalabrutinib, a highly selective, covalent, Bruton’s tyrosine kinase inhibitor in combination with the CD20 antibody obinutuzumab. Adult patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL) receiving at least 1 prior therapy were eligible for study participation. In 28-day cycles, acalabrutinib was given orally at a dose of 100 mg twice daily, or 200 mg once daily until disease progression. Obinutuzumab was given in standard fashion for 6 cycles starting with cycle 2. The primary end points were overall response rate (ORR) and safety, and secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival and minimal residual disease (MRD). Assessment of MRD in peripheral blood and in bone marrow was performed using flow cytometry.

A total of 19 treatment-naïve and 26 relapsed/refractory patients were treated with acalabrutinib plus obinutuzumab. The median age of all patients was 61 years. A substantial proportion of treatment-naïve and relapsed/refractory patients had high-risk disease characteristics, including del17p (22% and 19%, respectively), del11q (28% and 35%, respectively), complex karyotype (42% and 56%, respectively), and unmutated IGHV (53% and 65%, respectively).

Common all-grade adverse events were upper respiratory tract infection (73%), weight gain (72%), maculopapular rash (66%), cough (64%), diarrhea (64%), headache (56%), and nausea (54%). The most frequently occurring grade 3 or 4 adverse events were decreased neutrophil count (24%), syncope (11%), decreased platelet count, increased weight, and cellulitis (9% each). There were 2 grade 3 bleeding events and 1 grade 3 atrial fibrillation event.

In terms of efficacy, after median follow-up of 39.4 and 42.1 months in the treatment-naïve and relapsed/refractory groups, respectively, the ORR was 95% and 92% for treatment-naïve and relapsed/refractory patients, respectively, with 6 (32%) treatment-naïve patients and 2 (8%) relapsed/refractory patients showing complete response. Median DOR and PFS was not reached for either treatment group. Higher MRD-negativity rates were seen in the bone marrow of treatment-naïve (26%) versus relapsed/refractory (15%) patients.

The researchers concluded that acalabrutinib plus obinutuzumab was well tolerated and yielded high response rates that were durable and deepened over time in treatment-naïve and relapsed/refractory patients with CLL.

Abstract 7500; Woyach JA, et al.

Related Items
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME